Skip to main content
SpringerLink
Log in

Körperliches Training effektiver als Ernährung und Medikamente allein

Sarkopenie: Wie kommt der Patient wieder zu Kräften?

Sarcopenia — how does the patient restore muscle strength again

  • FORTBILDUNG . ÜBERSICHT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Sarkopenie wird als ein progressiver und generalisierter Verlust von Muskelmasse und Muskelfunktion verstanden. Damit ist eine erhöhte Wahrscheinlichkeit für z. B. Stürze, Frakturen, körperliche Behinderung und Mortalität verbunden. Was können Sie Ihren Patienten in Bezug auf Prävention und Therapie raten?

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. McLean RR, Shardell MD, Alley DE, Cawthon PM, Fragala MS, Harris TB, Kenny AM, Peters KW, Ferrucci L, Guralnik JM, Kritchevsky SB, Kiel DP, Vassileva MT, Xue Q-L, Perera S, Studenski SA, Dam T-TL. Criteria for clinically relevant weakness and low lean mass and their longitudinal association with incident mobility impairment and mortality: the foundation for the National Institutes of Health (FNIH) sarcopenia project. J. Gerontol. A. Biol. Sci. Med. Sci. 2014;69(5):576–83.

    Article  Google Scholar 

  2. Beaudart C, Zaaria M, Pasleau F, Reginster J-Y, Bruyère O. Health Outcomes of Sarcopenia: A Systematic Review and Meta-Analysis. PLoS One 2017;12(1):e0169548.

    Article  Google Scholar 

  3. Malmstrom TK, Miller DK, Simonsick EM, Ferrucci L, Morley JE. SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J. Cachexia. Sarcopenia Muscle 2016;7(1):28–36.

    Article  Google Scholar 

  4. Beaudart C, McCloskey E, Bruyère O, Cesari M, Rolland Y, Rizzoli R, Araujo de Carvalho I, Amuthavalli Thiyagarajan J, Bautmans I, Bertière MC, Brandi ML, Al-Daghri NM, Burlet N, Cavalier E, Cerreta F, Cherubini A, Fielding R, Gielen E, Landi F, Petermans J, Reginster JY, Visser M, Kanis J, Cooper C. Sarcopenia in daily practice: assessment and management. BMC Geriatr. 2016;16(1):1–10.

    Article  Google Scholar 

  5. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M, Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) and the EG for E. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2018;(1):1–16.

    Article  Google Scholar 

  6. Landi F, Liperoti R, Russo A, Giovannini S, Tosato M, Capoluongo E, Bernabei R, Onder G. Sarcopenia as a risk factor for falls in elderly individuals: Results from the ilSIRENTE study. Clin. Nutr. 2012;31(5):652–658.

    Article  Google Scholar 

  7. Huo YR, Suriyaarachchi P, Gomez F, Curcio CL, Boersma D, Gunawardene P, Demontiero O, Duque G. Comprehensive nutritional status in sarco-osteoporotic older fallers. J. Nutr. Heal. Aging 2015;19(4):474–480.

    Article  CAS  Google Scholar 

  8. Peterson MD, Sen A, Gordon PM. Influence of resistance exercise on lean body mass in aging adults: a meta-analysis. Med. Sci. Sports Exerc. 2011;43(2):249–58.

    Article  Google Scholar 

  9. Papa E V., Dong X, Hassan M. Resistance training for activity limitations in older adults with skeletal muscle function deficits: A systematic review. Clin. Interv. Aging 2017;12:955–961.

    Article  Google Scholar 

  10. Fiatarone MA, Marks EC, Ryan ND, Meredith CN, Lipsitz LA, Evans WJ. High-intensity strength training in nonagenarians. Effects on skeletal muscle. JAMA 1990;263(22):3029–34.

    Article  CAS  Google Scholar 

  11. Corbett DB, Rejeski WJ, Tudor-Locke C, Glynn NW, Kritchevsky SB, McDermott MM, Church TS, Fielding RA, Gill TM, King AC, Miller ME, Chen H, Pahor M, Manini TM. Social Participation Modifies the Effect of a Structured Physical Activity Program on Major Mobility Disability Among Older Adults: Results From the LIFE Study. Journals Gerontol. Ser. B 2017;00(00):1–13.

  12. Corcoran MP, Nelson ME, Sacheck JM, Reid KF, Kirn D, Fielding RA, Folta SC. Recruitment of mobility limited older adults into a facility-led exercise-nutrition study: The effect of social involvement. Gerontologist 2016;56(4):669–676.

    Article  Google Scholar 

  13. Peters A. The selfish brain: Competition for energy resources. Am. J. Hum. Biol. 2011;23(1):29–34.

    Article  Google Scholar 

  14. Cederholm T, Jensen GL, Correia MITD, Gonzalez MC, Fukushima R, Higashiguchi T, Baptista G, Barazzoni R, Blaauw R, Coats A, Crivelli A, Evans DC, Gramlich L, Fuchs-Tarlovsky V, Keller H, Llido L, Malone A, Mogensen KM, Morley JE, Muscaritoli M, Nyulasi I, Pirlich M, Pisprasert V, de van der Schueren MAE, Siltharm S, Singer P, Tappenden K, Velasco N, Waitzberg D, Yamwong P, Yu J, Van Gossum A, Compher C, GLIM Core Leadership Committee, GLIM Working Group. GLIM criteria for the diagnosis of malnutrition - A consensus report from the global clinical nutrition community. Clin. Nutr. 2018. doi:https://doi.org/10.1016/j.clnu.2018.08.002.

    Article  CAS  Google Scholar 

  15. Ikizler TA, Cano NJ, Franch H, Fouque D, Himmelfarb J, Kalantar-Zadeh K, Kuhlmann MK, Stenvinkel P, Terwee P, Teta D, Wang AYM, Wanner C. Prevention and treatment of protein energy wasting in chronic kidney disease patients: A consensus statement by the International Society of Renal Nutrition and Metabolism. Kidney Int. 2013;84(6):1096–1107.

    Article  CAS  Google Scholar 

  16. Perry HM, Horowitz M, Morley JE, Patrick P, Vellas B, Baumgartner R, Garry PJ. Longitudinal changes in serum 25-hydroxyvitamin D in older people. Metabolism. 1999;48(8):1028–32.

    Article  CAS  Google Scholar 

  17. Nieschlag E. Current topics in testosterone replacement of hypogonadal men. Best Pract. Res. Clin. Endocrinol. Metab. 2015;29(1):77–90.

    Article  CAS  Google Scholar 

  18. Crawford JC, Johnston MA, Hancock ML, Small SG, Taylor RP, Dalton JT, Steiner MS. Enobosarm, a selective androgen receptor modulator (SARM), increases lean bodymass (LBM) in advanced nsclc patients; updated results of two pivotal, international phase 3 trials. Support. care cancer 2014;22(1 SUPPL. 1):S30–S31.

    Google Scholar 

  19. Crawford J, Prado CMM, Johnston MA, Gralla RJ, Taylor RP, Hancock ML, Dalton JT. Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials). Curr. Oncol. Rep. 2016;18(6). doi:https://doi.org/10.1007/s11912-016-0522-0.

  20. Rooks D, Praestgaard J, Hariry S, Laurent D, Petricoul O, Perry RG, Lach-Trifilieff E, Roubenoff R. Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof-of-Concept Study. J. Am. Geriatr. Soc. 2017;65(9):1988–1995.

    Article  Google Scholar 

  21. Becker C, Lord SR, Studenski SA, Warden SJ, Fielding RA, Recknor CP, Hochberg MC, Ferrari SL, Blain H, Binder EF, Rolland Y, Poiraudeau S, Benson CT, Myers SL, Hu L, Ahmad QI, Pacuch KR, Gomez E V, Benichou O, STEADY Group. Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial. lancet. Diabetes Endocrinol. 2015;3(12):948–57.

    Article  CAS  Google Scholar 

  22. Band MM, Sumukadas D, Struthers AD, Avenell A, Donnan PT, Kemp PR, Smith KT, Hume CL, Hapca A, Witham MD. Leucine and ACE inhibitors as therapies for sarcopenia (LACE trial): study protocol for a randomised controlled trial. Trials 2018;19(1):6.

    Article  Google Scholar 

  23. Pötsch MS, Tschirner A, Palus S, von Haehling S, Doehner W, Beadle J, Coats AJS, Anker SD, Springer J. The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats. J. Cachexia. Sarcopenia Muscle 2014;5(2):149–158.

    Article  Google Scholar 

  24. Sumukadas D, Witham MD, Struthers AD, McMurdo MET. Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial. CMAJ 2007;177(8):867–74.

    Article  Google Scholar 

  25. Morley JE. Pharmacologic Options for the Treatment of Sarcopenia. Calcif. Tissue Int. 2016;98(4):319–333.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Studienzentrum Osteosarkopenie, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Schwerpunkt Akutgeriatrie, Ziemssenstrasse 1, D-80336, München, Deutschland

    Uta Ferrari &  Michael Drey MSc

Authors
  1. Uta Ferrari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Drey MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Drey MSc.

Additional information

Zusatzmaterial online

Zu diesem Beitrag ist unter www.springermedizin.de/mmw Zusatzmaterial abrufbar: - Tab. 1: Screeningfragebogen für Sarkopenie

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ferrari, U., Drey, M. Sarkopenie: Wie kommt der Patient wieder zu Kräften?. MMW - Fortschritte der Medizin 161, 45–48 (2019). https://doi.org/10.1007/s15006-019-0455-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-019-0455-2

Keywords

Search

Navigation